Review Papers Claim by Claim

1. Core claim and clinical impact: Markman et al. synthesize evidence showing KRAS codon 12/13 activating mutations predict resistance to anti‑EGFR monoclonal antibodies (cetuximab, panitumumab) in metastatic colorectal cancer (mCRC), and recommend routine KRAS testing before prescribing these agents — a recommendation that influenced policy and practice Markman 2010: main claim and evidence.
2. Evidence strength & consistency: The review draws from multiple single-arm and randomized trials and aggregated analyses (tables summarizing response rates and survival by KRAS). Its main conclusion (KRAS mutation is a negative predictive biomarker) is supported by later guideline and pooled-evidence updates (extended RAS testing) ASCO 2016 RAS testing update.
3. What the review did well:
   • Clear mechanistic framing (EGFR → RAS → RAF/MEK/ERK and PI3K/Akt) tying biology to clinical outcomes and testing rationale Pathway explanation in review.
   • Practical evaluation of testing methods (sequencing vs allele-specific PCR, ARMS, sensitivity trade-offs) — useful operational guidance for labs.
4. Limitations, blindspots and biases (critical):
   • Temporal: published 2010 — predates extended RAS/NRAS knowledge and many later clinical trials and KRAS‑G12C-targeted therapies; useful historically but incomplete for 2024+ practice. (See ASCO 2016 update for extended RAS) ASCO 2016 extended RAS
   • Heterogeneity & confounding: review relies on many retrospective analyses and some small single‑center series; risk of publication bias and incomplete prospective validation for some ancillary biomarkers (PTEN IHC, PIK3CA exon specifics, EGFR GCN, ligand expression) — the paper notes these are exploratory.
   • Clinical nuance: certain KRAS subtypes (e.g., G13D) later generated debate about partial sensitivity; Markman et al. summarize early signals but cannot resolve subtype-specific effects; subsequent pooled and prospective studies give mixed signals On KRAS subtype notes in review.
5. Reproducibility & methods transparency: The review collates published trial results and methodological notes on KRAS testing; it does not provide original datasets but points to the assays/limits (sequencing sensitivity, PCR sensitivity). For reproducibility, a reader must consult the primary trials and methodological studies cited (review gives clear signposts). See sequencing vs PCR comparative work cited in review and later meta-analyses KRAS testing methods in review and 2014 meta-analysis on KRAS testing methods.
6. Where the field moved after this review (succinct):
   • Extended RAS testing (KRAS exons 3/4 and NRAS) became standard; ASCO update formalized this (2016) ASCO guideline.
   • Work expanded to resistance mechanisms and combination strategies (BRAF, PI3K/PTEN, RTKs), and to direct KRAS targeting (G12C) with EGFR combinations now showing activity in CRC cohorts — these developments post‑date the review and complement its roadmap rather than contradict it.
7. Practical recommendation for a reader (clinician or researcher):

   Use this review as a high-quality 2010-era synthesis: it robustly justifies KRAS exon 2 testing as a negative predictive biomarker for anti‑EGFR mAbs and provides practical lab guidance. For current practice, always consult extended-RAS guidelines and recent trials on KRAS G12C and combination regimens (EGFR + KRASG12C) for therapy selection.

Bottom-line: Markman et al. (2010) provided a timely, well-referenced synthesis demonstrating that KRAS exon‑2 activating mutations are a robust negative predictive biomarker for anti‑EGFR monoclonal antibodies in mCRC and advocated for routine KRAS testing; this conclusion is supported and extended by later guideline-level evidence (extended RAS). The review correctly flags additional candidate markers (BRAF, PIK3CA, PTEN, EGFR GCN, EREG/AREG) but appropriately treats them as exploratory given mixed prospective validation.

Confidence grade for the review's central claim (KRAS exon 2 → resistance to anti-EGFR mAbs): high — consistent, replicated across multiple retrospective and prospective datasets and codified by practice guidelines (ASCO) ASCO recommendation supporting KRAS predictive role.